{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:45:21Z","timestamp":1791319521367,"version":"4.3.1"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:00:00Z","timestamp":1379635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00401-013-1177-7","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T10:57:04Z","timestamp":1379588224000},"page":"479-497","source":"Crossref","is-referenced-by-count":373,"title":["The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy"],"prefix":"10.1007","volume":"126","author":[{"given":"Patrick L.","family":"McGeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith G.","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,20]]},"reference":[{"key":"1177_CR1","doi-asserted-by":"crossref","unstructured":"ADAPT Research Group (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer\u2019s disease anti-inflammatory prevention trial (ADAPT). PLOS. doi: 10.1371\/journal.pctr.0010033","DOI":"10.1371\/journal.pctr.0010033"},{"key":"1177_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH et al (2011) Tramiprosate in mild to moderate Alzheimer\u2019s disease- a randomized, double blind, placebo-controlled, multi-center study (the Alphase study). Arch Med Sci 7:102\u2013104","journal-title":"Arch Med Sci"},{"key":"1177_CR3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M et al (2003) Effects of rofecoxib or naproxen vs. placebo on Alzheimer\u2019s disease progression: a randomized controlled trial. JAMA 289:2819\u20132826","journal-title":"JAMA"},{"key":"1177_CR4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","volume":"58","author":"PS Aisen","year":"2002","unstructured":"Aisen PS, Schmeidler J, Pasinetti GM (2002) Randomized pilot study of nimesulide treatment in Alzheimer\u2019s disease. Neurology 58:1050\u20131054","journal-title":"Neurology"},{"key":"1177_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm0204-117","volume":"10","author":"H Akiyama","year":"2004","unstructured":"Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after A\u03b2 immunotherapy for Alzheimer disease. Nature Med 10:117\u2013118","journal-title":"Nature Med"},{"key":"1177_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3940(96)12474-5","volume":"206","author":"H Akiyama","year":"1996","unstructured":"Akiyama H, Schwab C, Kondo H et al (1996) Granules in glial cells of patients with Alzheimer\u2019s disease are immunopositive for C-terminal sequences of beta-amyloid protein. Neurosci Lett 206:169\u2013172","journal-title":"Neurosci Lett"},{"key":"1177_CR7","doi-asserted-by":"crossref","unstructured":"Anon (1994) The Canadian Study of Health and Aging: risk factors for Alzheimer\u2019s disease in Canada. Neurology 44: 2073\u20132080","DOI":"10.1212\/WNL.44.11.2073"},{"key":"1177_CR8","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.54.11.2066","volume":"54","author":"JC Anthony","year":"2000","unstructured":"Anthony JC, Breitner JC, Zandi PP et al (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54:2066\u20132071","journal-title":"Neurology"},{"key":"1177_CR9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3233\/JAD-2009-1087","volume":"17","author":"GW Arendish","year":"2009","unstructured":"Arendish GW, Mori T, Cao C et al (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer\u2019s disease mice. J Alzheimer\u2019s Dis 17:661\u2013680","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1177_CR10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1212\/01.wnl.0000313813.48505.86","volume":"70","author":"Z Arvenitakis","year":"2008","unstructured":"Arvenitakis Z, Grodstein F, Schneider JA et al (2008) Relation of NSAIDs to incident AD, change in cognitive function and AD pathology. Neurology 70:2219\u20132225","journal-title":"Neurology"},{"key":"1177_CR11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1212\/WNL.0b013e31826c197f","volume":"79","author":"C Ballon","year":"2012","unstructured":"Ballon C, Griffith LE, Strifler L et al (2012) Vitamin D, cognition, and dementia: a systemic review and meta-analysis. Neurology 79:1397\u20131405","journal-title":"Neurology"},{"issue":"9","key":"1177_CR12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benziger TLS et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. New Engl J Med 367(9):793\u2013804","journal-title":"New Engl J Med"},{"key":"1177_CR13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4065\/73.10.951","volume":"73","author":"CM Beard","year":"1988","unstructured":"Beard CM, Waring SC, O\u2019Brien PC et al (1988) Nonsteroidal anti-inflammatory drug use and Alzheimer\u2019s disease: a case control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 73:951\u2013955","journal-title":"Mayo Clin Proc"},{"key":"1177_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2377-10-108","volume":"10","author":"F Bermajo-Parejo","year":"2010","unstructured":"Bermajo-Parejo F, Antequera D, Vargas JA et al (2010) Saliva levels of Abeta1\u201342 as potential biomarker of Alzheimer\u2019s disease: a pilot study. BMC Neurol 10:108","journal-title":"BMC Neurol"},{"key":"1177_CR15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blenow","year":"2012","unstructured":"Blenow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebral biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002\u20131010","journal-title":"Arch Neurol"},{"key":"1177_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259","journal-title":"Acta Neuropathol"},{"key":"1177_CR17","unstructured":"Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-b changes occur before increases of tau in spinal fluid. Acta Neuropathol PMID:23756600"},{"key":"1177_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1212\/WNL.44.2.227","volume":"44","author":"JC Breitner","year":"1994","unstructured":"Breitner JC, Gau BA, Welsh KA et al (1994) Inverse association of anti-inflammatory treatments and Alzheimer\u2019s disease: initial results of a co-twin control study. Neurology 44:227\u2013232","journal-title":"Neurology"},{"key":"1177_CR19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0197-4580(95)00049-K","volume":"16","author":"JC Breitner","year":"1995","unstructured":"Breitner JC, Welsh KA, Helms MJ et al (1995) Delayed onset of Alzheimer\u2019s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16:523\u2013530","journal-title":"Neurobiol Aging"},{"key":"1177_CR20","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1161591","volume":"321","author":"DL Brody","year":"2008","unstructured":"Brody DL, Magnoni S, Schwetye KE et al (2008) Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321:1221\u20131224","journal-title":"Science"},{"key":"1177_CR21","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archneur.57.11.1586","volume":"57","author":"GA Broe","year":"2000","unstructured":"Broe GA, Grayson DA, Creasy HM et al (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57:1586\u20131591","journal-title":"Arch Neurol"},{"key":"1177_CR22","unstructured":"Bruck A, Virta JR, Koiyunen J et al (2013) [11C]PIB, {18F}FDG and MY imaging in patients with mild cognitive impairment. Eur J Nucl Med Imaging PMID:23801168"},{"issue":"1","key":"1177_CR23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H et al (2012) Cerebrospinal fluid levels of \u03b2-amyloid 1-42, but not of tau, are fully changed already 5 to 10\u00a0years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1):98\u2013106","journal-title":"Arch Gen Psychiatry"},{"key":"1177_CR24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0306-4522(02)00056-8","volume":"112","author":"T Bussiere","year":"2002","unstructured":"Bussiere T, Friend N, Sadegh B et al (2002) Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer\u2019s disease. Neuroscience 112:75\u201381","journal-title":"Neuroscience"},{"issue":"3","key":"1177_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/JAD-2002-4309","volume":"4","author":"DA Butterfield","year":"2002","unstructured":"Butterfield DA, Griffin S, Munch G, Pasinetti GM (2002) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer disease brain exists. J Alzheimers Dis 4(3):193\u2013201","journal-title":"J Alzheimers Dis"},{"key":"1177_CR26","doi-asserted-by":"crossref","unstructured":"Cacquevel M, Aesschbach l, Houacine J, Fraering PC (2012) Alzheimer disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified \u03b3-secretase. PLOS One. doi: 10.1371\/journal.pone.0035133","DOI":"10.1371\/journal.pone.0035133"},{"key":"1177_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","volume":"124","author":"SH Choi","year":"2013","unstructured":"Choi SH, Aid S, Caracciolo L et al (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer\u2019s disease. J Neurochem 124:59\u201368","journal-title":"J Neurochem"},{"key":"1177_CR28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.foodchem.2012.04.148","volume":"135","author":"YE Chu","year":"2012","unstructured":"Chu YE, Chang WH, Black RM et al (2012) Crude caffeine reduces memory impairment and amyloid \u03b2(1-42) levels in an Alzheimer\u2019s mouse model. Food Chem 135:2095\u20132102","journal-title":"Food Chem"},{"key":"1177_CR29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, van Dyck CH, Salloway S et al (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","journal-title":"Arch Neurol"},{"key":"1177_CR30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.imbio.2011.07.017","volume":"217","author":"H Crehan","year":"2012","unstructured":"Crehan H, Holton P, Wray S et al (2012) Complement receptor 1 (CR1) and Alzheimer\u2019s disease. Immunobiology 217:244\u2013250","journal-title":"Immunobiology"},{"key":"1177_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/187152710791012080","volume":"9","author":"DH Cribbs","year":"2010","unstructured":"Cribbs DH (2010) Abeta DNA vaccination for Alzheimer\u2019s disease: focus on disease prevention. CNS Neurol Disord Drug Targets 9:207\u2013216","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1177_CR32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","volume":"22","author":"P Das","year":"2001","unstructured":"Das P, Murphy MP, Younkin LH et al (2001) Reduced effectiveness of A\u03b21-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721\u2013727","journal-title":"Neurobiol Aging"},{"key":"1177_CR33","doi-asserted-by":"crossref","first-page":"8550","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ et al (2001) Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 98:8550\u20138555","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR34","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1523\/JNEUROSCI.1189-06.2006","volume":"26","author":"A Deshpande","year":"2006","unstructured":"Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26:6011\u20136018","journal-title":"J Neurosci"},{"issue":"4","key":"1177_CR35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer disease. New Engl J Med 369(4):341\u2013350","journal-title":"New Engl J Med"},{"key":"1177_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/17460441.2012.645534","volume":"7","author":"G D\u2019Onofrio","year":"2012","unstructured":"D\u2019Onofrio G, Panza F, Frisardi V et al (2012) Advances in the identification of \u03b3-secretase inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Discov 7:19\u201337","journal-title":"Expert Opin Drug Discov"},{"key":"1177_CR37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00685397","volume":"57","author":"P Eikelenboom","year":"1982","unstructured":"Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques in Alzheimer\u2019s dementia. Acta Neuropathol 57:239\u2013242","journal-title":"Acta Neuropathol"},{"key":"1177_CR38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2353\/ajpath.2008.070620","volume":"172","author":"SS El-Amouri","year":"2008","unstructured":"El-Amouri SS, Zhu H, Yu J et al (2008) Neprilysin: an enzyme candidate to slow the progression of Alzheimer\u2019 disease. Am J Pathol 172:1342\u20131354","journal-title":"Am J Pathol"},{"key":"1177_CR39","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.287.24.3223","volume":"287","author":"MJ Engelhart","year":"2002","unstructured":"Engelhart MJ, Geerlings M, Ruitenberg A et al (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287:3223\u20133229","journal-title":"JAMA"},{"key":"1177_CR40","unstructured":"Eskilinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 20(Suppl 1): S167\u2013S174"},{"issue":"1","key":"1177_CR41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-2094-8-4","volume":"8","author":"MI Fonseca","year":"2011","unstructured":"Fonseca MI, Chu SH, Berci AM et al (2011) Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer disease. J Neuroinflamm 8(1):4. doi: 10:1186\/1742-2094-8-4","journal-title":"J Neuroinflamm"},{"key":"1177_CR42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00001756-199305000-00015","volume":"4","author":"G Forloni","year":"1993","unstructured":"Forloni G, Chiesa R, Smiroldo S et al (1993) Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. NeuroReport 4:523\u2013526","journal-title":"NeuroReport"},{"key":"1177_CR43","first-page":"3","volume":"18","author":"JC Frohlich","year":"1997","unstructured":"Frohlich JC (1997) A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. TIPS 18:3\u201334","journal-title":"TIPS"},{"key":"1177_CR44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0895-4356(96)00202-8","volume":"49","author":"A Fourier","year":"1996","unstructured":"Fourier A, Letenneur I, Begaud B, Dartigues JF (1996) Nonsteroidal anti-inflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 49:1201","journal-title":"J Clin Epidemiol"},{"key":"1177_CR45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","volume":"373","author":"D Games","year":"1995","unstructured":"Games D, Adams D, Allesandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523\u2013527","journal-title":"Nature"},{"key":"1177_CR46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3233\/JAD-2010-101428","volume":"23","author":"RP Gelber","year":"2011","unstructured":"Gelber RP, Petrovich H, Masaki KH et al (2011) Coffee intake in midlife and risk of dementia and its neuropathological correlates. J Alzheimer\u2019s Dis 23:607\u2013615","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"Suppl 1","key":"1177_CR47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","volume":"120","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Brindisi M, Tang J (2012) Developing beta-secretase inhibitors for treatment of Alzheimer\u2019s disease. J Neurochem 120(Suppl 1):71\u201383","journal-title":"J Neurochem"},{"key":"1177_CR48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885\u2013890","journal-title":"Biochem Biophys Res Commun"},{"key":"1177_CR49","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease and Down\u2019s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131\u20131135","journal-title":"Biochem Biophys Res Commun"},{"key":"1177_CR50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","volume":"391","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin M-C, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 391:704\u2013706","journal-title":"Nature"},{"key":"1177_CR51","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1073\/pnas.85.11.4051","volume":"85","author":"M Goedert","year":"1988","unstructured":"Goedert M, Wischik RA, Crowther J et al (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85:4051\u20134055","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.3810169","volume":"235","author":"D Goldgaber","year":"1987","unstructured":"Goldgaber D, Lerman MI, McBride OW et al (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer\u2019s disease. Science 235:877\u2013880","journal-title":"Science"},{"issue":"19","key":"1177_CR53","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86(19):7611\u20137615","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR54","doi-asserted-by":"crossref","first-page":"44913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC et al (1986) Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:44913\u201344917","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J et al (2013) TREM 2 variants in Alzheimer\u2019s disease. New Engl J Med 368:117\u2013127","journal-title":"New Engl J Med"},{"key":"1177_CR56","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3233\/JAD-2010-1331","volume":"19","author":"J-P Guo","year":"2010","unstructured":"Guo J-P, Yu S, McGeer PL (2010) Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer\u2019s disease therapy. J Alzheimers Dis 19:1359\u20131370","journal-title":"J Alzheimers Dis"},{"key":"1177_CR57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12:383\u2013388","journal-title":"Trends Pharmacol Sci"},{"key":"1177_CR58","doi-asserted-by":"crossref","unstructured":"Harold D, Abraham R, Hollingworth P et al Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet 41:1088\u20131093","DOI":"10.1038\/ng.440"},{"key":"1177_CR59","unstructured":"Hatashita S, Yamasaki H (2009) Diagnosed mild cognitive impairment due to Alzheimer\u2019s disease with PET biomarkers of beta amyloid and neuronal dysfunction. PloS One. doi: 10.1371\/journal.pone\/0066877"},{"key":"1177_CR60","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.neurobiolaging.2012.07.001","volume":"33","author":"LN Hazrati","year":"2012","unstructured":"Hazrati LN, Cauwenberghe C, Brooks PL et al (2012) Genetic association of CR1 with Alzheimer\u2019s disease: a tentative disease mechanism. Neurobiol Aging 33:2949","journal-title":"Neurobiol Aging"},{"key":"1177_CR61","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","volume":"128","author":"MT Heneka","year":"2005","unstructured":"Heneka MT, Sastre M, Dumitrescu-Ozimek L et al (2005) Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV171 transgenic mice. Brain 128:1442\u20131453","journal-title":"Brain"},{"key":"1177_CR62","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","volume":"10","author":"DB Henley","year":"2009","unstructured":"Henley DB, May PC, Dean RA, Siemers ER (2009) Development of semegacestat (LY450129), a functional gamma-secretase inhibitor, for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother 10:1657\u20131664","journal-title":"Expert Opin Pharmacother"},{"key":"1177_CR63","doi-asserted-by":"crossref","unstructured":"Hillman A, Hahn S, Schilling S et al (2012) No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer\u2019s disease. Neurobiol Aging 33:833","DOI":"10.1016\/j.neurobiolaging.2011.08.006"},{"key":"1177_CR64","first-page":"1","volume":"330","author":"J Hippisley-Cox","year":"2006","unstructured":"Hippisley-Cox J, Coupland C (2006) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 330:1\u20137","journal-title":"BMJ"},{"issue":"77","key":"1177_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3002369","volume":"3","author":"D Holtzman","year":"2011","unstructured":"Holtzman D, Morris JC, Goate AM (2011) Alzheimer\u2019s disease: the challenge of the second century. Sci Transl Med 3(77):1\u201317","journal-title":"Sci Transl Med"},{"key":"1177_CR66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D et al (2008) Long term effects of Ab42 immunization in Alzheimer\u2019s disease: follow-up of a randomized, placebo-controlled phase 1 trial. Lancet 372:216\u2013223","journal-title":"Lancet"},{"key":"1177_CR67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.290.5489.150","volume":"290","author":"L Hong","year":"2000","unstructured":"Hong L, Koelsch G, Lin X et al (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290:150\u2013153","journal-title":"Science"},{"key":"1177_CR68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","volume":"274","author":"K Hsiao","year":"1996","unstructured":"Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99\u2013102","journal-title":"Science"},{"key":"1177_CR69","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/oxfordjournals.jbchem.a135662","volume":"99","author":"Y Ihara","year":"1986","unstructured":"Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer\u2019s disease. J Biochem 99:1807\u20131810","journal-title":"J Biochem"},{"key":"1177_CR70","first-page":"113","volume":"60","author":"S Ikeda","year":"1989","unstructured":"Ikeda S, Allsop D, Glenner GG (1989) Morphology and distribution of plaque and related deposits in the brains of Alzheimer\u2019s disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab Invest 60:113\u2013122","journal-title":"Lab Invest"},{"key":"1177_CR71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","volume":"8","author":"BP Imbimbo","year":"2012","unstructured":"Imbimbo BP, Ottonello S, Frisardi V et al (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer\u2019s disease. Expert Rev Clin Immunol 8:135\u2013149","journal-title":"Expert Rev Clin Immunol"},{"key":"1177_CR72","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","volume":"345","author":"BA Int Veldt","year":"2001","unstructured":"Int Veldt BA, Ruttenberg A, Hofman A et al (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer\u2019s disease. N Engl J Med 345:1515\u20131521","journal-title":"N Engl J Med"},{"key":"1177_CR73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","volume":"108","author":"N Iwata","year":"2005","unstructured":"Iwata N, Higuchi M, Saido TC (2005) Metabolism of amyloid-beta peptide and Alzheimer\u2019s disease. Pharmacol Ther 108:129\u2013148","journal-title":"Pharmacol Ther"},{"key":"1177_CR74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/72237","volume":"6","author":"N Iwata","year":"2000","unstructured":"Iwata N, Tsubuki Y, Takaki K et al (2000) Identification of the major A beta (1-42) degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nature Med 6:143\u2013150","journal-title":"Nature Med"},{"key":"1177_CR75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer pathological cascade. Lancet Neurol 9:119\u2013128","journal-title":"Lancet Neurol"},{"key":"1177_CR76","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","volume":"22","author":"PT Jantzen","year":"2002","unstructured":"Jantzen PT, Connor KE, diCarlo G et al (2002) Microglial activation and beta amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246\u20132254","journal-title":"J Neurosci"},{"key":"1177_CR77","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C, Pearson J, McLaurin J et al (2000) A beta-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature 408:970\u2013982","journal-title":"Nature"},{"key":"1177_CR78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S et al (2013) Variant of TREM 2 associated with the risk of Alzheimer\u2019s disease. New Engl J Med 368:107\u2013116","journal-title":"New Engl J Med"},{"key":"1177_CR79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-0447.1987.tb02906.x","volume":"76","author":"AF Jorm","year":"1987","unstructured":"Jorm AF, Korten AE, Henderson AS (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76:465\u2013470","journal-title":"Acta Psychiatr Scand"},{"key":"1177_CR80","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000095267","volume":"3","author":"C Kaether","year":"2006","unstructured":"Kaether C, Haass C, Steiner H (2006) Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 3:275\u2013283","journal-title":"Neurodegener Dis"},{"key":"1177_CR81","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.neurobiolaging.2012.08.017","volume":"34","author":"N Kakuda","year":"2013","unstructured":"Kakuda N, Akazawa K, Hatsuta H et al (2013) Suspected limited efficacy of \u03b3-secretase inhibitors. Neurobiol Aging 34:1101\u20131104","journal-title":"Neurobiol Aging"},{"key":"1177_CR82","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/bi015685+","volume":"41","author":"W Kalback","year":"2002","unstructured":"Kalback W, Watson MD, Kokjohn TA et al (2002) APP transgenic mice TG2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer\u2019s disease senile plaques. Biochemistry 41:922\u2013928","journal-title":"Biochemistry"},{"key":"1177_CR83","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","volume":"33","author":"R Katzman","year":"1976","unstructured":"Katzman R (1976) The prevalence and malignancy of Alzheimer\u2019s disease: a major killer. Arch Neurol 33:217\u2013218","journal-title":"Arch Neurol"},{"key":"1177_CR84","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1073\/pnas.93.6.2317","volume":"93","author":"WE Kaufmann","year":"1996","unstructured":"Kaufmann WE, Worley PF, Pegg J et al (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at post synaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317\u20132321","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1096\/fj.01-0987fje","volume":"17","author":"HJ Kim","year":"2003","unstructured":"Kim HJ, Chae SC, Lee DK et al (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17:118\u2013120","journal-title":"FASEB J"},{"key":"1177_CR86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2004.04.001","volume":"152","author":"A Klegeris","year":"2004","unstructured":"Klegeris A, Maguire J, McGeer PL (2004) S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell toxicity. J Neuroimmunol 152:73\u201377","journal-title":"J Neuroimmunol"},{"key":"1177_CR87","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jalz.2007.11.008","volume":"4","author":"AD Korczyn","year":"2008","unstructured":"Korczyn AD (2008) The amyloid cascade hypothesis. Alzheimer Dementia 4:176\u2013178","journal-title":"Alzheimer Dementia"},{"key":"1177_CR88","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.83.11.4044","volume":"83","author":"KS Kosik","year":"1986","unstructured":"Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83:4044\u20134048","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm1235","volume":"11","author":"T Kukar","year":"2005","unstructured":"Kukar T, Murphy MP, Erikson JL et al (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A\u03b2 42 production. Nature Med 11:545\u2013550","journal-title":"Nature Med"},{"key":"1177_CR90","doi-asserted-by":"crossref","unstructured":"Kukar T, Prescott S, Erikson JL et al (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor mice. BMC Neurosci 8:54","DOI":"10.1186\/1471-2202-8-54"},{"key":"1177_CR91","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1074\/jbc.M007859200","volume":"276","author":"YM Kuo","year":"2001","unstructured":"Kuo YM, Kokjohn TA, Beach TG et al (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer\u2019s disease brains. J Biol Chem 276:12991\u201312998","journal-title":"J Biol Chem"},{"key":"1177_CR92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000093478","volume":"22","author":"MH Laitenen","year":"2006","unstructured":"Laitenen MH, Ngandu T, Rovio S et al (2006) Fat intake at midlife and risk of dementia and Alzheimer\u2019s disease: a population- based study. Dement Geriatr Cogn Disord 22:99\u2013107","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1177_CR93","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00019442-200303000-00008","volume":"11","author":"F Landi","year":"2003","unstructured":"Landi F, Cesari M, Onder G et al (2003) Non-steroidal anti-inflammatory drug use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiat 11:179\u2013185","journal-title":"Am J Geriatr Psychiat"},{"key":"1177_CR94","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","volume":"421","author":"SL Laporte","year":"2012","unstructured":"Laporte SL, Bollini SS, Lanz TA et al (2012) Structural basis of C-terminal \u03b2-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease. J Mol Biol 421:525\u2013536","journal-title":"J Mol Biol"},{"key":"1177_CR95","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.neurobiolaging.2011.12.005","volume":"33","author":"M Lee","year":"2012","unstructured":"Lee M, Guo JP, Schwab C et al (2012) Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol Aging 33:2237\u20132246","journal-title":"Neurobiol Aging"},{"key":"1177_CR96","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","volume":"68","author":"GG Leiketsos","year":"2007","unstructured":"Leiketsos GG (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68:1800\u20131808","journal-title":"Neurology"},{"key":"1177_CR97","author":"JM Leoutsakos","year":"2011","unstructured":"Leoutsakos JM, Multhen BO, Breitner JC et al (2011) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline by phase of pre-clinical Alzheimer disease: findings from the randomized control Alzheimer\u2019s disease anti-inflammatory prevention trial. Int J Geriatr Psychiatry. doi: 10:1002\/gps.2723","journal-title":"Int J Geriatr Psychiatry"},{"key":"1177_CR98","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levi-Lahad","year":"1995","unstructured":"Levi-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial disease locus. Science 269:973\u2013977","journal-title":"Science"},{"key":"1177_CR99","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1126\/science.2111584","volume":"248","author":"E Levy","year":"1990","unstructured":"Levy E, Carman MD, Fernandez-Madrid IJ et al (1990) Mutation of the Alzheimer\u2019s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124\u20131126","journal-title":"Science"},{"key":"1177_CR100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/JAD-2012-120349","volume":"31","author":"FJ Li","year":"2012","unstructured":"Li FJ, Shen L, Ji HE (2012) Dietary intakes of vitamin E, vitamin C, and \u03b2-carotene and risk of Alzheimer\u2019s disease: a meta-analysis. J Alzheimer\u2019s Dis 31:253\u2013258","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1177_CR101","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","volume":"20","author":"GP Lim","year":"2000","unstructured":"Lim GP, Yang F, Chu T et al (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer\u2019s disease. J Neurosci 20:5709\u20135714","journal-title":"J Neurosci"},{"key":"1177_CR102","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0197-4580(01)00299-8","volume":"22","author":"JP Lim","year":"2001","unstructured":"Lim JP, Yang P, Chu T et al (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22:983\u2013991","journal-title":"Neurobiol Aging"},{"key":"1177_CR103","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/aje\/kwf074","volume":"158","author":"J Lindsay","year":"2002","unstructured":"Lindsay J, Laurin D, Verrault R et al (2002) Risk factors for Alzheimer\u2019s disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol 158:445\u2013453","journal-title":"Am J Epidemiol"},{"key":"1177_CR104","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.1073\/pnas.91.25.12243","volume":"125","author":"A Lorenzo","year":"1994","unstructured":"Lorenzo A, Yankner BA (1994) Beta amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 125:12243\u201312247","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/EDE.0b013e3182944410","volume":"24","author":"I Lourida","year":"2013","unstructured":"Lourida I, Soni M, Thompson-Coon J et al (2013) Mediterranean diet, cognitive function and dementia: a systemic review. Epidemiology 24:479\u2013489","journal-title":"Epidemiology"},{"key":"1177_CR106","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","volume":"64","author":"K Ma","year":"2012","unstructured":"Ma K, Thomason LA, McLaurin J (2012) Scyllo-inositol, preclinical, and clinical data for Alzheimer disease. Adv Pharmacol 64:177\u2013212","journal-title":"Adv Pharmacol"},{"key":"1177_CR107","doi-asserted-by":"crossref","unstructured":"Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer\u2019s disease? Eur J Neurol, pp 377\u2013382","DOI":"10.1046\/j.1468-1331.2002.00421.x"},{"key":"1177_CR108","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2011","unstructured":"Mangialasche F, Solomon A, Winblad B et al (2011) Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol 9:702\u2013716","journal-title":"Lancet Neurol"},{"key":"1177_CR109","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA et al (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 82:4245\u20134249","journal-title":"Proc Natl Acad Sci"},{"key":"1177_CR110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3233\/JAD-2012-120019","volume":"30","author":"N Mattsson","year":"2012","unstructured":"Mattsson N, Portelius E, Rolstad S et al (2012) Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimer\u2019s Dis 30:767\u2013778","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1177_CR111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0197-4580(92)90064-5","volume":"13","author":"PC May","year":"1992","unstructured":"May PC, Gitter BD, Waters DC et al (1992) Beta amyloid peptide in vitro toxicity: lot to lot toxicity. Neurobiol Aging 13:605\u2013607","journal-title":"Neurobiol Aging"},{"key":"1177_CR112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0304-3940(89)90843-4","volume":"107","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Activation of the complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107:341\u2013346","journal-title":"Neurosci Lett"},{"key":"1177_CR113","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1017\/S0317167100029863","volume":"16","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Immune response in Alzheimer\u2019s disease. Can J Neurol Sci 16:516\u2013527","journal-title":"Can J Neurol Sci"},{"key":"1177_CR114","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0197-4580(02)00157-4","volume":"24","author":"PL McGeer","year":"2003","unstructured":"McGeer PL, McGeer EG (2003) Is there a future for vaccination as a treatment for Alzheimer\u2019s disease. Neurobiol Aging 24:391\u2013395","journal-title":"Neurobiol Aging"},{"key":"1177_CR115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0140-6736(90)91101-F","volume":"335","author":"PL McGeer","year":"1990","unstructured":"McGeer PL, McGeer EG, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer disease. Lancet 335:107","journal-title":"Lancet"},{"key":"1177_CR116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tig.2006.03.007","volume":"22","author":"E McGowan","year":"2006","unstructured":"McGowan E, Eriksen L, Hutton M (2006) A decade of modeling Alzheimer\u2019s disease in transgenic mice. Trends Genet 22:281\u2013289","journal-title":"Trends Genet"},{"key":"1177_CR117","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1097\/NEN.0b013e3181a9d503","volume":"68","author":"AC McKee","year":"2009","unstructured":"McKee AC, Cantu RC, Nowinski CJ et al (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68:2709\u20132735","journal-title":"J Neuropath Exp Neurol"},{"key":"1177_CR118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2008.01.095","volume":"1207","author":"AC McKee","year":"2008","unstructured":"McKee AC, Carreras I, Hossain L et al (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207:225\u2013236","journal-title":"Brain Res"},{"key":"1177_CR119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/brain\/aws307","volume":"136","author":"AC McKee","year":"2013","unstructured":"McKee AC, Stein TD, Nowinski CJ et al (2013) The spectrum of disease in chronic traumatic encephalopathy. Brain 136:43\u201364","journal-title":"Brain"},{"key":"1177_CR120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottscall PE et al (2000) Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature 408:982\u2013985","journal-title":"Nature"},{"key":"1177_CR121","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1471-4159.2002.01195.x","volume":"83","author":"T Morihara","year":"2002","unstructured":"Morihara T, Chu T, Ubeda O et al (2002) Selective inhibition of A\u03b242 production by R-enantiomers. J Neurochem 83:1009\u20131012","journal-title":"J Neurochem"},{"key":"1177_CR122","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrd3842","volume":"11","author":"A Mullard","year":"2012","unstructured":"Mullard A (2012) String of Alzheimer\u2019s failures offset by upcoming prevention trials. Nature Rev Drug Discov 11:657\u2013660","journal-title":"Nature Rev Drug Discov"},{"issue":"Suppl 1","key":"1177_CR123","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","volume":"120","author":"NN Naliivaeva","year":"2012","unstructured":"Naliivaeva NN, Beckett C, Belyaev ND, Turner AJ (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer\u2019s disease. J Neurochem 120(Suppl 1):167\u2013185","journal-title":"J Neurochem"},{"key":"1177_CR124","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JAR Nicoll","year":"2003","unstructured":"Nicoll JAR, Wilkinson D, Holmes C et al (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report. Nature Med 9:448\u2013452","journal-title":"Nature Med"},{"key":"1177_CR125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneurol.2010.334","volume":"68","author":"OC Okonko","year":"2011","unstructured":"Okonko OC, Miellke MM, Griffith HR et al (2011) Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol 68:113\u2013119","journal-title":"Arch Neurol"},{"key":"1177_CR126","doi-asserted-by":"crossref","unstructured":"Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106:14745\u201314750","DOI":"10.1073\/pnas.0905127106"},{"key":"1177_CR127","doi-asserted-by":"crossref","unstructured":"Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"1177_CR128","doi-asserted-by":"crossref","unstructured":"Pasaqualletti P, Bonomini C, Dal Forno G et al (2009) A randomized controlled study on the effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease. Aging Clin Exp Res 21:102\u2013110","DOI":"10.1007\/BF03325217"},{"issue":"Suppl 1","key":"1177_CR129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1471-4159.2011.07459.x","volume":"120","author":"R Postina","year":"2012","unstructured":"Postina R (2012) Activation of \u03b1-secretase cleavage. J Neurochem 120(Suppl 1):46\u201354","journal-title":"J Neurochem"},{"issue":"11","key":"1177_CR130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","volume":"80","author":"A Prestia","year":"2013","unstructured":"Prestia A, Caroll A, van der Flier WM et al (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80(11):1048\u20131056","journal-title":"Neurology"},{"key":"1177_CR131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-5728(03)00037-7","volume":"137","author":"J Quinn","year":"2003","unstructured":"Quinn J, Montine T, Morrow J et al (2003) Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer disease. J Neuroimmunol 137:32\u201341","journal-title":"J Neuroimmunol"},{"key":"1177_CR132","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","volume":"62","author":"SA Reines","year":"2004","unstructured":"Reines SA, Block GA, Morris JC et al (2004) Rofecoxib: no effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66\u201371","journal-title":"Neurology"},{"key":"1177_CR133","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(87)91754-5","volume":"1","author":"NK Robakis","year":"1987","unstructured":"Robakis NK, Wisniewski HM, Jenkins EC et al (1987) Chromosome 21q21 sublocalization of gene encoding beta-amyloid-peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1:384\u2013385","journal-title":"Lancet"},{"key":"1177_CR134","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1073\/pnas.89.21.10016","volume":"89","author":"J Rogers","year":"1992","unstructured":"Rogers J, Cooper NR, Webster S et al (1992) Complement activation by beta-amyloid in Alzheimer\u2019s disease. Proc Natl Acad Sci USA 89:10016\u201310020","journal-title":"Proc Natl Acad Sci USA"},{"key":"1177_CR135","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","volume":"43","author":"J Rogers","year":"1993","unstructured":"Rogers J, Kirby LC, Hempelman SC et al (1993) Clinical trial of indomethacin in Alzheimer\u2019s disease. Neurology 43:1609\u20131611","journal-title":"Neurology"},{"issue":"4","key":"1177_CR136","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00019052-199608000-00004","volume":"9","author":"AD Roses","year":"1993","unstructured":"Roses AD (1993) Apolipoprotein E in neurology. Curr Opin Neurol 9(4):265\u2013270","journal-title":"Curr Opin Neurol"},{"key":"1177_CR137","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"S Salloway","year":"2011","unstructured":"Salloway S, Sperling R, Karen R et al (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77:1253\u20131262","journal-title":"Neurology"},{"key":"1177_CR138","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1471-4159.2011.07213.x","volume":"117","author":"K Sambamurti","year":"2011","unstructured":"Sambamurti K, Greig NH, Tadanobu U et al (2011) Targets for AD treatment: conflicting messages from \u03b3-secretase inhibitors. J Neurochem 117:359\u2013374","journal-title":"J Neurochem"},{"key":"1177_CR139","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","volume":"53","author":"S Scharf","year":"1999","unstructured":"Scharf S, Mander A, Ugoni A et al (1999) A double blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease. Neurology 53:197\u2013201","journal-title":"Neurology"},{"key":"1177_CR140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173\u2013177","journal-title":"Nature"},{"key":"1177_CR141","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/156720509787313871","volume":"6","author":"LS Schneider","year":"2008","unstructured":"Schneider LS, Lahiri DK (2008) The perils of Alzheimer\u2019s drug development. Curr Alzheimer Res 6:77\u201378","journal-title":"Curr Alzheimer Res"},{"key":"1177_CR142","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.expneurol.2004.03.016","volume":"188","author":"C Schwab","year":"2004","unstructured":"Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188:52\u201364","journal-title":"Exp Neurol"},{"key":"1177_CR143","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ (1991) The molecular pathology of Alzheimer\u2019s disease. Neuron 6:403\u2013409","journal-title":"Neuron"},{"issue":"4","key":"1177_CR144","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czaika M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65(4):403\u2013413","journal-title":"Ann Neurol"},{"issue":"20","key":"1177_CR145","doi-asserted-by":"crossref","first-page":"11568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Seppala","year":"2012","unstructured":"Seppala TT, Nerg O, Koivisto AM et al (2012) CSF biomarkers for Alzheimer disease correlate with brain atrophy findings. Neurology 78(20):11568\u201311575","journal-title":"Neurology"},{"key":"1177_CR146","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375:754\u2013760","journal-title":"Nature"},{"key":"1177_CR147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096588","volume":"23","author":"H Soininen","year":"2007","unstructured":"Soininen H, West C, Robbins J, Niculescu L (2007) Long term efficacy and safety of celecoxib in Alzheimer\u2019s disease. Dementia Geriatr Cogn Disord 23:8\u201321","journal-title":"Dementia Geriatr Cogn Disord"},{"key":"1177_CR148","doi-asserted-by":"crossref","unstructured":"Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dementia, pp 280\u2013292","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"1177_CR149","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12:609\u2013622","journal-title":"Lancet Neurol"},{"key":"1177_CR150","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/archneur.65.7.906","volume":"65","author":"JR Steinerman","year":"2008","unstructured":"Steinerman JR, Irizarry M, Scarmeas N et al (2008) Distinct pools of beta-amyloid in Alzheimer\u2019s disease-affected brain: a clinicopathologic study. Arch Neurol 65:906\u2013912","journal-title":"Arch Neurol"},{"key":"1177_CR151","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"RA Stelzman","year":"1995","unstructured":"Stelzman RA, Schnitlen HN, Murtagh FR (1995) An English translation of Alzheimer\u2019s 1907 paper. Clin Anat 8:429\u2013431","journal-title":"Clin Anat"},{"key":"1177_CR152","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.48.3.626","volume":"48","author":"WF Stewart","year":"1997","unstructured":"Stewart WF, Klawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer disease and duration of NSAID use. Neurology 48:626\u2013632","journal-title":"Neurology"},{"key":"1177_CR153","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0002-9440(10)63269-5","volume":"165","author":"S Sung","year":"2004","unstructured":"Sung S, Yang Y, Uryu K et al (2004) Modulation of nuclear factor \u03baB activity by indomethacin influences A\u03b2 levels but not A\u03b2 precursor protein metabolism in a model of Alzheimer\u2019s disease. Am J Pathol 165:2197\u20132206","journal-title":"Am J Pathol"},{"key":"1177_CR154","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/01.wnl.0000313933.17796.f6","volume":"70","author":"CA Szekely","year":"2008","unstructured":"Szekely CA, Green RC, Breitner JH (2008) No advantage of A\u03b242-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70:2291\u20132298","journal-title":"Neurology"},{"key":"1177_CR155","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","volume":"13","author":"HO Tayeb","year":"2013","unstructured":"Tayeb HO, Murray ED, Price BH, Tarazi FI (2013) Bapineuzamab and solanezumab for Alzheimer\u2019s disease: is the amyloid cascade hypothesis still alive? Expert Opin Biol Ther 13:1075\u20131084","journal-title":"Expert Opin Biol Ther"},{"key":"1177_CR156","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"M Theis","year":"2013","unstructured":"Theis M, Bleiler S (2013) Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dem 9:208\u2013245","journal-title":"Alzheimer\u2019s Dem"},{"key":"1177_CR157","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Shaw LM, Trojanowski JQ (2013) Plasma amyloid beta measurements: a desired but elusive Alzheimer\u2019s disease marker. Alzheimer\u2019s Res Ther 5:8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1177_CR158","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1126\/science.1971458","volume":"248","author":"C Broeckhoven Van","year":"1990","unstructured":"Van Broeckhoven C, Haan J, Bakker E et al (1990) Amyloid beta protein precursor gene and hereditary cerebral hemorrhage, Dutch type. Science 248:1120\u20131122","journal-title":"Science"},{"key":"1177_CR159","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881108097630","volume":"24","author":"D Dam Van","year":"2010","unstructured":"Van Dam D, Coen K, de Deyn PP (2010) Ibuprofen modifies cognitive disease progression in an Alzheimer\u2019s mouse model. J Psychopharmacol 24:383\u2013388","journal-title":"J Psychopharmacol"},{"key":"1177_CR160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.brainresrev.2004.12.026","volume":"48","author":"T Groen Van","year":"2005","unstructured":"Van Groen T, Kadish I (2005) Transgenic model mice, effects of potential AD treatments on inflammation and pathology. Brain Res Rev 48:370\u2013378","journal-title":"Brain Res Rev"},{"key":"1177_CR161","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JAD-2011-101479","volume":"24","author":"T Groen Van","year":"2011","unstructured":"Van Groen T, Miettinen P, Kadish I (2011) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation. J Alzheimer\u2019s Dis 24:301\u2013313","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1177_CR162","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735\u2013741","journal-title":"Science"},{"key":"1177_CR163","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. doi: 10.1016\/S1474-4442(13)70044-9","journal-title":"Lancet Neurol"},{"key":"1177_CR164","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser PJ, Verhey F, Knol DL et al (2009) Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8:619\u2013627","journal-title":"Lancet Neurol"},{"key":"1177_CR165","doi-asserted-by":"crossref","unstructured":"Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70:1672\u20131677","DOI":"10.1212\/01.wnl.0000311269.57716.63"},{"issue":"5","key":"1177_CR166","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.22608","volume":"70","author":"AG Vlassenko","year":"2011","unstructured":"Vlassenko AG, Mintun MA, Xiong C et al (2011) Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C] Pittsburgh compound B data. Ann Neurol 70(5):857\u2013861","journal-title":"Ann Neurol"},{"key":"1177_CR167","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jnutbio.2009.01.012","volume":"31","author":"PY Wang","year":"2010","unstructured":"Wang PY, Chen JJ, Su HM (2010) Docosohexaenoic acid supplementation of primary hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein(42) and up-regulates cytoskeletal protein expression. J Nutr Biochem 31:345\u2013350","journal-title":"J Nutr Biochem"},{"key":"1177_CR168","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-4580(97)00042-0","volume":"18","author":"SD Webster","year":"1997","unstructured":"Webster SD, Lue F, Brachova L et al (1997) Molecular and cellular characterization of the membrane attack complex C5b-9 in Alzheimer\u2019s disease. Neurobiol Aging 18:415\u2013421","journal-title":"Neurobiol Aging"},{"key":"1177_CR169","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-4580(97)00042-0","volume":"18","author":"SD Webster","year":"1999","unstructured":"Webster SD, Tenner AJ, Paulos TL et al (1999) The mouse C1q A-chain sequence alters beta-amyloid\u2013induced complement activation. Neurobiol Aging 18:415\u2013421","journal-title":"Neurobiol Aging"},{"key":"1177_CR170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, Erikson JL, Das P et al (2001) A subset of NSAIDs lower amyloidogenic A\u03b242 independently of cyclooxygenase activity. Nature 414:212\u2013216","journal-title":"Nature"},{"key":"1177_CR171","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0197-4580(89)90079-1","volume":"10","author":"HM Wisniewski","year":"1989","unstructured":"Wisniewski HM, Iqbal K, Banchewr C et al (1989) Cytoskeletal pathology and the formation of beta-amyloid fibers in Alzheimer\u2019s disease. Neurobiol Aging 10:409\u2013414","journal-title":"Neurobiol Aging"},{"issue":"Suppl 2","key":"1177_CR172","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2202-9-S2-S5","volume":"9","author":"T Wisniewski","year":"2008","unstructured":"Wisniewski T, Sadowski M (2008) Preventing \u03b2-amyloid fibrillization and deposition: \u03b2-sheet breakers and pathological chaperone inhibitors. BMC Neurosci 9(Suppl 2):55","journal-title":"BMC Neurosci"},{"key":"1177_CR173","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-394816-8.00004-0","volume":"64","author":"MS Wolfe","year":"2012","unstructured":"Wolfe MS (2012) \u03b3-Secretase as a target for Alzheimer\u2019s disease. Adv Pharmacol 64:127\u2013153","journal-title":"Adv Pharmacol"},{"key":"1177_CR174","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000048621","volume":"21","author":"C Wolfson","year":"2002","unstructured":"Wolfson C, Perrault A, Moride Y et al (2002) A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer disease: are they protective? Neuroepidemiology 21:81\u201386","journal-title":"Neuroepidemiology"},{"key":"1177_CR175","unstructured":"Wyss-Coray T, Yan F, Lin AH et al (2009) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer\u2019s mice. Proc Natl Acad Sci USA, pp 10837\u201310842"},{"key":"1177_CR176","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archneurol.2008.565","volume":"66","author":"W Xia","year":"2009","unstructured":"Xia W, Yang T, Shankar G et al (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66:190\u2013199","journal-title":"Arch Neurol"},{"key":"1177_CR177","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","volume":"23","author":"Q Yan","year":"2003","unstructured":"Yan Q, Zhang J, Liu H et al (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer\u2019s disease. J Neurosci 23:7504\u20137509","journal-title":"J Neurosci"},{"key":"1177_CR178","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1126\/science.2474201","volume":"245","author":"BA Yankner","year":"1989","unstructured":"Yankner BA, Dawes LR, Fisher S et al (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer\u2019s disease. Science 245:417\u2013420","journal-title":"Science"},{"key":"1177_CR179","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(01)03008-6","volume":"919","author":"K Yasojima","year":"2001","unstructured":"Yasojima K, McGeer EG, McGeer PL (2001) Relationship between beta amyloid peptide generation molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 919:115\u2013121","journal-title":"Brain Res"},{"key":"1177_CR180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2318-5-2","volume":"5","author":"AG Yip","year":"2005","unstructured":"Yip AG, Green RC, Huyck M et al (2005) Non steroidal anti-inflammatory drug use and Alzheimer\u2019s disease risk: the Mirage study. BMC Geriatr 5:2","journal-title":"BMC Geriatr"},{"key":"1177_CR181","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.wad.0000165506.60370.94","volume":"19","author":"H Zanjani","year":"2005","unstructured":"Zanjani H, Finch CE, Kemper C et al (2005) Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 19:55\u201356","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1177_CR182","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.59.6.880","volume":"59","author":"PP Zandi","year":"2002","unstructured":"Zandi PP, Anthony JC, Hayden KM et al (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists. The Cache County study. Neurology 59:880\u2013886","journal-title":"Neurology"},{"key":"1177_CR183","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-2007-12307","volume":"12","author":"H Zetterberg","year":"2007","unstructured":"Zetterberg H, Pedersen M, Lind K et al (2007) Intra-individual stability of CSF biomarkers for Alzheimer\u2019s disease over two years. J Alzheimer\u2019s Dis 12:255\u2013260","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1177_CR184","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/j.1471-4159.2008.05558.x","volume":"106","author":"J Zhou","year":"2008","unstructured":"Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ (2008) Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer\u2019s disease. J Neurochem 106:2080\u20132092","journal-title":"J Neurochem"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-013-1177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-013-1177-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-013-1177-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:01:03Z","timestamp":1563951663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-013-1177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,20]]},"references-count":184,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s00401-013-1177-7","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,20]]}}}